Published in Vaccine Weekly, June 12th, 2002
The National Foundation for Infectious Diseases (NFID), a sponsor of the conference, issued a press release highlighting the clinical trial results of StreptAvax. The StreptAvax presentation was chosen by NFID because it "represents cutting edge development in the field, and holds great promise for improving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly